TPI-287

Star0

DB17168InvestigationalSmall molecule

TPI-287: Overview.

Mechanism: Pharmacologically active on Tubulin
Curator reviewed
Formula / weight: C₄₆H₆₃NO₁₅ · 870.002 g/mol (avg)
Also known as: (2'R,3'S)-2'-hydroxy-N-carboxy-3'-amino-5'-methyl-hexanoic,N-tert-butyl ester, 13 ester 5B-20-epoxy-1B,2a,4a,7B,9a,10a,13a-heptahydroxy-4,10-diacetate-2-benzoate-(1"S)-7,9-acrolein acetal-11(15-1)-abeotaxane
Code names: TPI-287

Resolves to

Compound

UNIIA2VM2V569ACAS849213-15-6

Structure

InChIKeyFDTAUJJRHBRHIJ-FDJAAIFISA-NSMILES

[H][C@@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@H](CC(C)C)NC(=O)OC(C)(C)C)C(C)=C([C@H](OC(C)=O)[C@@H]4OC(O[C@@H](C[C@H]5OC[C@@]15OC(C)=O)[C@]24C)C=C)C3(C)C

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which companies are running trials of TPI-287, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account